Braveheart Bio, Inc. Common Stock (BRVE)

Braveheart Bio, Inc. Common Stock (BRVE) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.9B; returns 1 day -0.2%, 1 week +14.6%.

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company that went public in August 2026, focusing on the development of small-molecule therapeutics for cardiovascular diseases.

Groups BRVE belongs to

• Recent IPOs
• Clinical Stage Biopharma
• Biopharmaceutical
• Cardiovascular Therapies
• Biotechnology
• Healthcare
• Clinical Stage

BRVE financial model: income statement, cash flow and balance sheet